141 related articles for article (PubMed ID: 9212845)
1. Concomitant p53 mutation and MYCN amplification in neuroblastoma.
Manhani R; Cristofani LM; Odone Filho V; Bendit I
Med Pediatr Oncol; 1997 Sep; 29(3):206-7. PubMed ID: 9212845
[TBL] [Abstract][Full Text] [Related]
2. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification.
Chen B; Jhanwar SC; Ladanyi M
Diagn Mol Pathol; 2001 Jun; 10(2):100-4. PubMed ID: 11385318
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma).
Lorenzana AN; Zielenska M; Thorner P; Gerrie B; Weitzman S; Squire J
Pediatr Pathol Lab Med; 1997; 17(6):875-83. PubMed ID: 9353827
[TBL] [Abstract][Full Text] [Related]
4. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
5. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification.
Imamura J; Bartram CR; Berthold F; Harms D; Nakamura H; Koeffler HP
Cancer Res; 1993 Sep; 53(17):4053-8. PubMed ID: 8358734
[TBL] [Abstract][Full Text] [Related]
6. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
7. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
8. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei.
Valent A; Bénard J; Clausse B; Barrois M; Valteau-Couanet D; Terrier-Lacombe MJ; Spengler B; Bernheim A
Am J Pathol; 2001 May; 158(5):1579-84. PubMed ID: 11337354
[TBL] [Abstract][Full Text] [Related]
9. Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J
Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849
[TBL] [Abstract][Full Text] [Related]
10. Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction.
Boerner S; Squire J; Thorner P; McKenna G; Zielenska M
Pediatr Pathol; 1994; 14(5):823-32. PubMed ID: 7808981
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues.
Misra DN; Dickman PS; Yunis EJ
Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
13. Association of N-myc amplification with neuroblastoma: the Australian and New Zealand experience.
Telford DJ; Kavallaris M; White L; Norris MD; Brian MJ; Stewart BW
J Paediatr Child Health; 1992 Feb; 28(1):58-63. PubMed ID: 1554517
[TBL] [Abstract][Full Text] [Related]
14. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
15. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
[TBL] [Abstract][Full Text] [Related]
16. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
17. Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients.
Brack T; Scholz RB; Milde-Langosch K; Heinsohn S; Löning T; Kabisch H
Cancer Detect Prev; 1992; 16(3):185-92. PubMed ID: 1458508
[TBL] [Abstract][Full Text] [Related]
18. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
19. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
20. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
